PolyActiva completes phase 1 study of biodegradable glaucoma implant
PolyActiva has completed a phase 1 clinical study evaluating the Latanoprost FA SR ocular implant for glaucoma treatment, according to a press release.
The implant was well tolerated in the eight study subjects and persisted for the 6-month treatment period. No significant safety findings were observed.
After the treatment period, the implant biodegrades over 6 weeks, which may allow for repeat dosing. The aim of the implant is to “provide a constant daily therapeutic dose of latanoprost free acid” for 6 months, the release said.
“Our goal is to improve the reduction of intraocular pressure by ensuring a constant daily dose of drug for the entire treatment period and offering the opportunity for repeated use,” Russell Tait, CEO of PolyActiva, said in the release. “Furthermore, the implant should reduce the frequency of conjunctival hyperemia and corneal surface disease side effects often seen with drop therapy.”
A phase 2 dose-ranging study is underway in Australia to determine the minimum effective dose of latanoprost free acid and confirm safety.